Nuvectis Pharma, Inc. (NVCT) Research

Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.

Market snapshot

Symbol
NVCT
Price
$13.82
Day change
+9.77%
Market cap
$366.6M
P/E ratio
-11.91x
52-week range
5.55-14.16
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$13.00

Peer companies

  • Armata Pharmaceuticals, Inc. (ARMP)
  • Compugen Ltd. (CGEN)
  • Cardiff Oncology, Inc. (CRDF)
  • Cybin Inc. (CYBN)
  • Innate Pharma S.A. (IPHA)
  • Milestone Pharmaceuticals Inc. (MIST)
  • Molecular Partners AG (MOLN)
  • Rani Therapeutics Holdings, Inc. (RANI)

Recent insider activity

  • Hoberman Kenneth — A-Award (35000 shares) on 2026-06-11
  • Oliviero James F III — A-Award (35000 shares) on 2026-06-11
  • Sanchez Juan — A-Award (35000 shares) on 2026-06-11
  • Kaplan Matthew L. — A-Award (35000 shares) on 2026-06-11
  • Shemesh Shay — A-Award (150000 shares) on 2026-01-06

Open Nuvectis Pharma, Inc. (NVCT) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.